RSI · Q2 FY27 · THE VERDICT

Record PAT Growth Masks a Revenue Engine at 2% Organic

Profit jumped 81.6% but only 2% came from organic revenue growth. Acquisition, FX, and margin expansion did the lifting — and the street isn't buying the growth story yet.

Q2 FY27 results RSYSTEMSR Systems International Limited10 Nov 2026 · 6 min read

Reported PAT

₹64.2 Cr

+81.6% YoY

Adjusted PAT

₹66.5 Cr

+53% YoY

Reported revenue growth

+23.4%

Only 2% organic

EBITDA margin

20.2%

vs 18–19% target

R Systems' Q2 PAT jumped 81.6% to ₹64.2 Crore — a headline demanding scrutiny. Dig one layer and the picture inverts: organic revenue grew just 2%, well below the 3–4% aspiration management restated a quarter ago, and TTM ACV bookings are flat despite the AI push. The profit is real, but it rests on margin expansion (20.2% EBITDA, beating guidance) and a ~₹7 Crore FX tailwind — not revenue acceleration.

What drove the 81.6% PAT jump

Reported PAT grew ₹29 Crore. Of that, organic revenue growth (2%) contributed maybe ₹1 Crore. Margin expansion — EBITDA margin moving from 16.9% to 20.2% on a larger nominal base — added roughly ₹20 Crore. FX tailwind (~₹7 Cr acknowledged) added another ₹7 Crore. Adjusted PAT ₹66.5 Crore (+53% YoY) is the cleaner organic proxy: profit grew sharply, but on operational discipline and currency help, not on growing the revenue line.

What management claimed vs. what holds up

Claims checked against delivered result and call substance

23.4% YoY revenue growth, strong momentum

Overstated

₹615.2 Cr vs ₹498.6 Cr LY. But organic +2% only; Novigo acquisition & FX tailwind account for 21 percentage points of the reported 23.4% growth.

7 continuous quarters of growth & margin improvement

Supported

PAT +81.6%, OPM 19.2% vs 16.9% LY, adjusted EBITDA 20.2% vs prior 16.9%. All confirmed.

TTM ACV bookings momentum, strong pipeline

Mixed

₹82.9M TTM ACV unchanged YoY. Management acknowledged flatness; attributed to strategic shift from many small to fewer large transformational deals (longer 3–4 month cycles).

AI revenue >35%, EXIOO/agentic traction

Partial

Claimed 'probably well over 35%' of revenue but unaudited. Early wins named (telecom modernization, finserv automation, insurance, entertainment). Tone confident, data unverified.

What changed on this call

Management pivoted strategy explicitly: from pure IT services/OPD to enterprise transformation and agentic AI. The EXIOO studio is live; large client wins in telecom, financial services, entertainment, and insurance are named and material. But the operational reality is concrete: deal cycles have extended to 3–4 months, and ACV counts are flat. Enterprise revenue is still ~15% of total (target: 25–35% in 2–3 years), so this is early-stage. Most materially, management dropped the 3–4% constant-currency growth aspiration and admitted Q2 organic is 2%, blamed on deal timing and cycle lengthening. That is an implicit guidance cut, even though unstated.

The bull-bear ledger

PAT +81.6%, margin beats target, 7 quarters of consistent growth
EBITDA 20.2% is above the 18–19% aspiration; operational leverage proven
Enterprise/AI strategy credible; named wins in verticals with clear ROI (telecom modernization, finserv automation)
Organic revenue growth stalled at 2%, vs prior 3–4% aspiration
TTM ACV bookings flat; deal cycle lengthening delays revenue and execution risk
AI revenue unaudited; >35% claim lacks third-party verification
Margin already at 20.2%, above target; limited upside buffer for further expansion
Geopolitical uncertainty (Middle East); Novigo integration ongoing

Risks, ranked by how much they should concern a holder

Organic growth stalled at 2% vs 3–4% prior target; no recovery timeline given

High

If organic doesn't reach 4%+ in the next 2 quarters, the growth narrative collapses entirely. Margin expansion alone cannot drive re-rating; revenue growth must inflect. Management hired a Chief Revenue Officer 2 qtrs ago but results not yet visible. Monitor Q3 organic growth — this is the line item that matters.

ACV bookings flat; deal cycles extending to 3–4 months

High

Deal count hasn't recovered. The shift to larger transformation deals is strategic, but flat bookings despite AI/enterprise focus signals weak pipeline or poor conversion. Q3/Q4 results will reveal whether deals are delayed or truly slowing. This is a bellwether.

Novigo integration, geopolitical headwind (Middle East)

Medium

Novigo (Saudi Arabia, UAE) is ~4% of revenue and growing, but management flagged 'tentativeness' in the Middle East due to conflict. If Novigo stalls, a 4–5% revenue headwind emerges in FY28. Track this separately in Q3 commentary.

Margin plateau at 20.2%; upside buffer limited

Medium

EBITDA is already above target (20.2% vs 18–19%). Management restated 'high 18s' (18.6–18.7%) as sustainable, suggesting 20%+ is not reliable. If organic growth stays at 2%, margin becomes the only story — and that's a ceiling, not a runway.

AI revenue unaudited; >35% claim unverified

Medium

Management said 'probably' when asked if AI is >35% of revenue; no audit trail. Segmentation changes could inflate the percentage without genuine new wins. This resolves or escalates once 3–4 quarters of formal tracking exist.

How the street is positioned

The stock trades at ₹264.3, below its 200-day average (₹270.33) and well below its 52-week high of ₹430.2 — a 55.88% drawdown from the peak. It sits above the 20-day and 50-day averages, suggesting modest recovery after the broader selloff. Volume is increasing, which can signal either accumulation or capitulation. FII holdings are effectively flat (3.82% in Q1 FY27 vs 3.76% a quarter ago), while DII trimmed 2.07 percentage points (from 8.60% to 6.53%). The bulk deals from early October show mixed activity — institutional players alternating buys and sells at ₹271–₹274 — but nothing dramatic or sustained. The market is treating this as a steady-state IT services operator, not a turnaround or growth inflection. That positioning is consistent with our fundamental read: profit is strong, but growth is stuck.

The debate

Bull case: PAT +81.6%, margins beat, AI/enterprise TAM is real, and management has credible wins (telecom, finserv, insurance, entertainment). In 2–3 years, if transformation work scales from 15% to 25–35% of revenue, margins sustain and organic growth re-inflects, the stock re-rates on higher growth at similar multiples. Bear case: Organic growth at 2% is a stall. ACV bookings flat despite AI push is a red flag. Management's admission of longer deal cycles suggests execution risk, not just timing. Margin expansion alone cannot drive valuation — multiples expand on growth, and the growth is missing. If organic doesn't hit 4%+ by Q4 FY27, the thesis fails and the stock trades as a low-growth IT vendor at a multiple discount. Honest read: The enterprise/AI pivot is credible but early-stage and unproven at scale. Profit delivery is strong because margin and FX picked up the slack. The real test is the next 2 quarters: does organic growth inflect toward mid-single digits, or does the 2% stall persist? Until then, this is a Hold — profitable but not yet a growth re-rating.

What to watch next

1 · Q3 organic revenue growth
The linchpin. If organic stays at 2%, the growth thesis breaks; if it reaches 3–4%+, the deal cycle lengthening was real timing delay. Monitor this number closely — it is the single metric that resolves the debate.
2 · ACV bookings and deal win rate
Track TTM ACV in Q3. If bookings remain flat but enterprise/AI revenue inflects (proving cycle delays are real), the risk lowers. If both stay flat, pipeline quality or conversion is in question.
3 · Enterprise revenue mix and deal size
Confirm the shift to larger transformational deals is real. If enterprise revenue reaches 18–20% of total in Q3, the strategy is working; if it stalls at 15%, the pivot has stalled too.

R Systems delivered a strong profit quarter — adjusted PAT up 53% driven by margin expansion and operational discipline. But the revenue engine is running on 2% organic growth, well below management's prior aspirations and below what the market calls inflection. The enterprise/AI transformation pivot is real and strategically sound; named wins in verticals with clear ROI are credible. But they're early wins, not scaled revenue yet. The next 2 quarters will tell whether this is a quarter-long timing delay or a structural slowdown. Until organic growth re-inflects toward mid-single digits, this remains a steady, well-managed company at a margin ceiling — not a growth story. Track the organic growth number from here.

Informational and educational content only. Not investment advice.